Main Titles
 


NEWS

Artificial Life Announces Partnership Agreement with Biotech Technology Leader BeFutur Biotechnologies S.A.

NEW YORK, GENEVA, and MONTREAL, Oct. 15 /PRNewswire/ -- New York based Artificial Life Inc. (OTC Bulletin Board: ALIF), a leading provider of award winning intelligent software robot (bot) technology and specialist for computational biotech applications, announced today that it has entered into a partnership agreement with the Swiss/Canadian privately held biotech company BeFutur Biotechnologies SA, a technology leader in stem cell research and regenerative medicine.

The two companies have agreed to co-operate in the areas of

-- stem cells research
-- simulation and analysis of cell growth patterns
-- regenerative medicine
-- product and vaccine development

"This is a great jump start for us in the biotech arena. Like us, BeFutur is a technology leader and an innovative and dynamically growing company with an enthusiastic founder and employees. We all are excited to co-operate with BeFutur to simulate cell growth patterns with our unique technology to speed up, improve and augment the manual lab research and product development at BeFutur. The potential of the combination of our simulation and data mining tools with the know-how and unique serum free cell technology of BeFutur is tremendous" said Eberhard Schoeneburg, CEO of Artificial Life.

"BeFutur Biotechnologies is honored to be associated with Artificial Life; their data mining and Alife simulation technology can be applied and adapted to all kinds of complex biotech data and stem cell development patterns. Our breakthrough results in stem cell research, combined with their algorithms derived from the study of living systems can have a tremendous impact in real life applications", said Carla-Maria Khanjian, Vice-President of BeFutur Biotechnologies SA.

About Artificial Life

Founded in 1994, Artificial Life, Inc. (OTC Bulletin Board: ALIF) develops, markets, and supports intelligent award winning and patent pending software robots and is a leading provider of data- and knowledge mining algorithms and biotech solutions. The company offers a variety of unique product suites for a wide variety of Internet based applications such as self-help, self-service, consultative selling, e-CRM, e-Finance and Mobile Computing. Major customers of Artificial Life include, among others, Advance Bank, Credit Suisse First Boston, Eagle Star, Liechtenstein Global Trust, MobilCom, Pioneer Investments, PricewaterhouseCoopers, UBS and ZDF.

Artificial Life, Inc. is headquartered in New York City, NY, U.S.A, and maintains a subsidiary in Hong Kong. Detailed information about Artificial Life, Inc. and its products is available at http://www.artificial-life.com

Contact: E.Schoeneburg, CEO Artificial Life, Inc.
E-mail: es@artificial-life.com

About BeFutur Biotechnologies

Founded in 1998, BeFutur Biotechnologies is a privately-held Swiss biotech company with a very specialized R&D team. BeFutur is on the forefront of research for harvesting adult autologous stem cells. It is the only company in the world that uses a totally animal serum free medium, thereby avoiding any risk of rejection and contamination. Its unique technology is based on a stable cell-culture method, which harvests cells usable in future cell therapies. Its research activities remain in stem cell differentiation to tissue engineering, with a primary focus on tissue regeneration. BeFutur Biotechnologies S.A. is headquartered in Geneva, Switzerland, with subsidiaries in Montreal, Canada and Mougins, France. More information can be obtained at: http://www.befutur.com

Contact: Carla-Maria Khanjian, VP, BeFutur Biotechnologies,
Email: carla@befutur.com

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Artificial Life, Inc.'s business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" described in the Company's Annual Report or Forms 10-K or 10-Q for the most recently ended fiscal year and quarter. All information set forth in this press release is as of August 20, 2001, and Artificial Life, Inc. undertakes no duty to update this information unless required by law.

BeFutur Biotechnologies is a registered trademark.

SOURCE Artificial Life, Inc.
Web Site: http://www.artificial-life.com


Breaking News on Stem Cells

Stem Cells research based on non-embryonic cells

BeFutur Biotechnologies is on the forefront of research for harvesting non-embryonic stem cells. It is the only company in the world that uses a totally animal serum free medium, in order to avoid any risk of contamination. Its technology is based on the cell-culture medium and its protocol: this particular medium plays a screening role, which is ideal in detecting the stem cells. Harvesting these real stem cells from adult stem cells requires an arduous task; BeFutur Biotechnologies is on its way to achieve that milestone.

The miracle cure offered by BeFutur

Moreover, BeFutur has, through its own research, elaborated a perfectly nutrient serum-free medium where cells can proliferate in a healthy and normal way. From another point of view, considering the actual controversy and possible ban on embryonic stem cell research, BeFutur Biotechnologies continues to watch its fantastic results poured in from its own non-embryonic stem cells research, based on adult autologous stem cells. "The adult autologous stem cells can function as well, perhaps even better, than stem cells", according to the R&D team of BeFutur Biotechnologies.


State of the art, cell-culture facility in Switzerland

BeFutur Biotechnologies and its subsidiaries are setting up an exclusive center in Switzerland, specialized in the culture of cells and tissues for therapeutic purposes. To date the phase of research and development in the fields of cardiology, bio-cosmetic, aesthetic medicine and parodontology is finished, and BeFutur is fully operational for the industrial phase and the marketing.


Sponsor at the Techvest's annual conference on Tissue Repair, Replacement and Regeneration

October 23-24 at Boston Marriott Long Wharf Hotel.


BeFutur Biotechnologies is a Gold Sponsor at The Second Annual Conference on Regenerative Medicine: Rebuilding the Human Body

December 2 - 4, Washington D.C., USA


BeFutur Biotechnologies presents breakthrough paper at the University of Geneva workshop: "Cardiac Aging, Heart Failure and Cell Therapy"

University of Geneva, Faculty of Medicine
September 27 - 29, Geneva, Switzerland


BeFutur Biotechnologies participates at BioContact 2001

October 10 - 12, Chateau Frontenac, Quebec
BioContact Québec 2001 is a biopharmaceutical partnership symposium
gathering over 1200 participants
www.biocontact.qc.ca

BeFutur Biotechnologies holds a seminar on Aesthetical Medicine in Belgium

October 31, La Woluwe, Belgium
Michel Zbili, M.D., Guest Speaker